Obesity Models and Efficacy Services
Obesity is a kind of metabolic disorder affected by many factors such as diet, environment and heredity. Besides weight gain, it may also lead to a series of complications such as diabetes, hypertension, hyperlipidemia and heart disease. In order to further study the obesity mechanism and evaluate related therapeutic drugs, GemPharmatech has developed a series of obesity mouse models, including diet-induced obesity model and spontaneous obesity model caused by gene mutation, and can provide drug efficacy evaluation services based on these models.
- Obesity Models
-
- 60% HFD diet-induced obesity (DIO) model: 60% high-fat diet-induced modeling.
- 45% HFHSD diet-induced obesity (DIO) model: 45% high-fat, high-sugar diet-induced modeling.
- Gene mutation obesity mouse model C57BL/6-Alms1-del: Alms1 gene fragment deletion, resulting in a combined phenotype of obesity, diabetes, and metabolic dysfunction-associated steatotic liver disease.
- Wild mouse 750: Conventional diet feeding can cause spontaneous obesity; 60% high-fat diet feeding can shorten the modeling cycle..
- Obesity-related target humanized mice.
- Test items:
-
- Body weight, food intake；
- Postprandial/fasting blood glucose, glycated hemoglobin (HbA1c), GTT/ ITT, blood biochemical test (ALT, AST, TG, CHOL, HDL-C, LDL-C, etc.), plasma insulin and other factors (based on ELISA Kit)；
- Body composition, physiological cage test (urine and feces collection), metabolic cage test (CO2 production, O2 consumption, heat, RER and activity)；
- Tissue and organ collection, histopathological analysis (H&E, Sirius Red, Masson, Oil Red, IHC staining etc.), and gene expression analysis (qRT-PCR & WB).